- Metastatic and/or advanced renal cell carcinoma patients treated with sunitinib in
first line according to the summary of product characteristics
- Resolution of all adverse event (grade ≤ 1 according to the Common Terminology
Criteria for Adverse Events v 4.3 of June 2010) from a prior treatment by radiotherapy
and/or surgery
- Patient who can be followed for 6 months
- Patient who has signed a consent form
- Patient affiliated to a national health service
- Sexually active fertile subjects and their partners must agree to use medically
accepted methods of contraception during the course of the study and for 28 days after
the last dose of study treatment
- Patient who is participating in another clinical study
- Patient taken in charge by a home help service
- Patient with brain metastases not treated or symptomatic
- Patient with an Eastern Cooperative Oncology Group at inclusion > 2
- Patient with a rate of serum creatinine > 1.5 times the upper limit normal
- Patient with a rate of bilirubin > 2 mg/dl
- Patient with a rate of aspartate transaminase (ASAT) or alanine transaminase (ALAT) >
2.5 times the upper limit normal or > 5 times the upper limit normal for patients with
hepatic metastases